
Alkermes Plc
ALKS · NASDAQ · Healthcare / Drug Manufacturers - Specialty & Generic
Price History
Full chartMarket Stats
About
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Company Details
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CEOMr. Joshua Reed M.B.A.
- Employees2.05K
- HeadquartersConnaught House, Dublin, Ireland, D04 C5Y6, USA
- Websitehttps://www.alkermes.com
Leadership
- Mr. Joshua Reed M.B.A.Senior VP & CFO · b. 1973
- Mr. David Joseph Gaffin J.D.Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary · b. 1972
- Dr. Craig C. Hopkinson M.D.Executive VP of Research & Development and Chief Medical Officer · b. 1969
- Mr. Christian Todd NicholsSenior VP & Chief Commercial Officer · b. 1970
- Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of Finance · b. 1975
- Mr. Tom SkoffSVP & Chief Information Officer
- Ms. Sandra CoombsSenior Vice President of Corporate Affairs & Investor Relations
- Mr. Stephen SchiavoSenior VP & Chief Human Resources Officer
- Mr. Peter NormanSVP of Policy, Government & Community Relations
- Mr. Declan O'ConnorSenior Vice President of Operations and Environment, Health & Safety
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy8
- Buy1
- Hold6
Ownership Breakdown
- Institutions
- 107.86%
- Insiders
- 1.40%
- Retail / Other
- 0.00%
Top Institutional Holders
- BlackRock Inc28.31M16.88%
- Baker Bros Advisors LP10.01M5.97%
- Vanguard Portfolio Management, LLC9.51M5.67%
- State Street Corp9.47M5.64%
- Vanguard Capital Management, LLC7.43M4.43%
- Renaissance Technologies Corp6.16M3.67%
- T. Rowe Price Associates, Inc.4.66M2.78%
- COMMODORE CAPITAL LP4.20M2.50%
- Dimensional Fund Advisors, Inc.4.19M2.50%
- Geode Capital Management, LLC4.18M2.49%
- JPMorgan Chase & Co4.10M2.44%
- Deep Track Capital, LP4.00M2.38%
- American Century Companies Inc3.95M2.36%
- Wellington Management Company LLP2.81M1.68%
- PRIMECAP Management Company2.53M1.51%
- Nuveen, LLC2.46M1.47%
Top Fund Holders
- iShares Core S&P Small-Cap ETF10.16M6.06%
- Vanguard MStar Total Stk Mkt Idx Invest5.31M3.16%
- iShares Russell 2000 ETF4.27M2.55%
- Vanguard Small Cap Index3.84M2.29%
Stock Splits
- May 15, 20002:1